gel-e Expands Clinical Advisory Board with more Surgical Talent

COLLEGE PARK, Md., Jan. 9, 2018 /PRNewswire/ -- gel-e, Inc., a clinical-stage medical device company developing versatile hemostatic products for surgical, medical, and consumer applications, announces the expansion of its Clinical Advisory Board (CAB) to include Dr. Grant Bochicchio, Chief of Acute and Critical Care Surgery at Washington University School of Medicine.  

gel-e's success and proven platform, that includes two US FDA-cleared hemostatic indications, have allowed the Company to continue to attract key talent http://www.gel-e.co/news.html.  Dr. Bochicchio brings significant expertise to gel-e from developing multiple marketed surgical hemostats.  His 130 peer reviewed articles and national presentations have been supported by ~$30M in funding from agencies such as DARPA, the Department of Defense and the National Institutes of Health.  As the designated Principal Investigator, Dr. Bochicchio has taken several advanced hemostats from the bench to the bedside, including a fibrin sealant patch and a fibrin sealant powder.  Dr. Bochicchio joins an impressive advisory board that includes key opinion leaders from Harvard/Mass General and Weill Cornell Medical Center.

"Dr. Bochicchio was involved as an early collaborator in published efficacy studies based on our biopolymer-based platform.  More recently, he's worked with us to test new product candidates." said Dr. Matthew Dowling, CSO of gel-e.  "It's exciting to have Grant collaborating with our current advisors on this project, adding to gel-e's reservoir of clinical insight and surgical talent to guide, evaluate and validate surgical and other hemostatic products."  

Visit http://www.gel-e.co/team.html to learn more about Dr. Bochicchio's background.

"I'm enthusiastic about joining the gel-e team," said Dr. Bochicchio. "The Company has built a solid scientific and regulatory foundation for external hemostasis and wound treatment and is poised to expand the platform into the surgical suite.  I'm looking forward to help the team at gel-e design and evaluate new products that can be integrated into routine surgical practice."

About the Company
gel-e is developing a novel line of hemostatic and wound treatment products. With an initial focus on external wounds, gel-e combines the use of safe, inert ingredients with proprietary chemistry that can be designed for use across a broad spectrum of clinical applications, including vascular closure and during surgery. gel-e is based in College Park, Md.

For additional information, please visit http://www.gel-e.co.

Contact:
Larry Tiffany, gel-e, Inc.
(301) 529-4943 
[email protected]

SOURCE gel-e, Inc.

Related Links

http://www.gel-e.co